Home » Newsletters » BioWorld Science

BioWorld Science

July 9, 2015

View Archived Issues

Novel NCSTN mutation may underlie familial hidradenitis suppurativa

Caspase-1 as a new target to prevent diabetic retinopathy

Daiichi Sankyo presents first-in-human results for DS-1040

First subject dosed in first-in-human study of ABX-1431

Summit Therapeutics' SMT-19969 receives FDA fast track designation

Novo Nordisk discontinues GLP-1 patch collaboration with Zosano

Manremyc signs Indian agreement for sale of food supplement to curb TB

Pfizer announces immunological disease collaboration

Roche and Genentech patent TYK2 kinase inhibitors

Actelion divulges new antibacterials

Gruenenthal reports development of CRAC inhibitors

Bayer Schering Pharma presents glucose transport inhibitors

Almirall reports JAK inhibitors

Merck Patent describes PDHK2 inhibitors

FDA accepts IND for trial using Viaskin Milk in milk-induced eosinophilic esophagitis

Oramed signs letter of intent for Chinese investment and licensing deal

Depomed board rejects acquisition proposal from Horizon Pharma

Tillotts acquires ex-U.S. rights to Entocort

Sernova receives funding for Cell Pouch type 1 diabetes collaboration

City of Hope launches clinical trial of immune suppression strategy in islet transplantation

Wayne State University receives grant to repurpose rosiglitazone for pre-eclampsia

Novartis starts phase II/III trial of PI3Kdelta inhibitor

Micell's sirolimus-eluting stent enters phase III trial in coronary heart disease

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Cosmo data positive for first new hair-loss approach in decades
BioWorld
Shares of Cosmo Pharmaceuticals NV rose sharply on Dec. 3 following top-line pivotal phase III data showing a statistically significant and clinically meaningful...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...